Ding Ting Ting, Gao Ting, Sequoia and other head organizations gathered, just completed the 400 million yuan B round of financing of the collection of medicine Kang in the end what charm?

On September 11th, Jiangsu Pharmaceuticals and Health Biotech Co., Ltd. officially announced the completion of more than 400 million yuan B round of financing.
round of financing is led by Gao Wei Ventures, Yunfeng Fund, Morgan Stanley, Sequoia Capital, Taifu Capital and other funds to participate in the investment.
this round of financing is mainly used for the construction of the company's Nanjing headquarters, the development of model animal products, as well as the development of domestic and foreign markets.
July 2019, the company completed a 160 million yuan round of A financing co-invested by Ding Yi Investment and State Pharmaceutical Holdings.
in just over a year, the company has once again been recognized by many of the top investment institutions on the front line, which is a good example of capital's recognition of the track and the leading companies. Founded on December 29, 2017,
Collections is a supplier of experimental animal seed resource centers and mouse models to support life sciences research and the development of pharmaceutical products and technologies by creating, producing and supplying animal models such as mice.
company has a leading gene editing, stem cell engineering, physiological and bio-functional analysis, new drug technology screening and other core technology platform.
company's revenue figures confirm the agency's judgment.
company was established three years ago, sales revenue to achieve explosive growth, in the first half of 2020, even under the impact of the epidemic, the company's industrial customers (drug companies) significantly increased, favored by domestic and foreign innovative pharmaceutical companies, revenue and profits are expected to achieve more than 50% growth this year.
is the market in which the drug is located? How does the company form its own competitiveness in this industry? Why is it popular with many of the top head investors? And after this round of financing, the company has what kind of capital operation plan? How big is the market? With the rapid aging of the population, the rising awareness of healthy consumption of residents, the release of industry policy dividends and other factors, the field of medical and health is attracting more and more venture capital institutions' attention.
especially in the context of this year's outbreak of neo-crown pneumonia, enterprises in the first and second-tier markets, such as innovative drugs, diagnostics, vaccine research and development, have received substantial capital investment and support.
but well-known fact is that although the success rate of early detection of drugs and preclinical studies is high, the failure rate of clinical studies is high.
, how to use the optimization of the preclinical evaluation phase of drugs through basic scientific research, early drug discovery, and drug preclinical evaluation may be the key to improving the efficiency of new drug research and development.
mouse model is the key to improving efficiency.
99 percent of the genes in mice can be found in the human genome, and the study is relatively clear, so the mice are considered a gold standard by medical research.
in modern medicine, there are few chemical and biological drugs that go directly to human clinical trials without going through mice.
, founder of
, said, "There are other model animals, such as dogs, pigs, monkeys, but because of cost and ethical issues, the use of preclinical trials will be more limited."
" data show that the demand for mice is growing steadily, both in terms of scientific research needs, early drug discovery, preclinical evaluation of drugs, and even clinical technology applications.
in terms of scientific research needs, China invests 130 billion yuan in basic research each year, and the U.S. NIH spends 30 billion U.S. dollars, or about 1.8 billion U.S. dollars, based on 4% of mouse costs.
and this market is growing at about 10% a year.
drug research and development, global drug companies spent 179 billion U.S. dollars on research and development in 2018, up 8% year-on-year.
If animal models are developed and put into use at 15% preclinical level, the market for animal models for new drug research and development in China alone will be about 3 billion yuan (up 20% annually) and the global capacity will be US$3.2 billion to $3.7 billion (an annual increase of 6.6%).
in drug research and development in new areas has grown more rapidly, and demand for corresponding mouse models has increased accordingly.
2017-2019, the number of cancer immunologic drugs in development increased from 2030 to 3,876, and the demand for tumor immunologic mouse models increased explosively.
microbiome functional analysis is absolutely dependent on animal models.
the global market for the human microbiome will reach $2.2 billion by 2020, according to Transparency Market Research, and is expected to grow at a compound annual rate of 9.8 percent from 2022 to 2024, worth $3.2 billion.
according to GMI data, the global mouse model market will exceed $6.9 billion in 2018 ($5.7 billion in the U.S., 90 million in the U.S.) and grow at an annual rate of more than 7 percent, with an estimated market of more than $11.7 billion over 25 years.
, however, huge market demand is facing the dilemma of shortage of resources.
in overseas markets, precision conditional knock-out of mouse line resources is only about 6,000 species, and most because of unclear property rights, commercial use is difficult.
, it's a huge market opportunity for the drug-collecting companies.
: Model resource scale is expected to be the world's largest mouse model resource size is the largest moth for the collection of drug kang.
less than three years after the establishment of the company, that is, with clear intellectual property rights of more than 10,000 mouse product line (of which in 2020 alone added nearly 4,000 product line), rat resources of nearly 300 species.
company is expected to overtake JAX as the world's largest mouse line of resources by the end of this year.
is also one of the largest platforms for global model animal creation capacity.
use of optimized gene editing technology, so that the project completion cycle is greatly shortened, the cost is greatly reduced, quality is also firmly in the forefront of the industry.
launched the Spotted Rat Program, which is expected to become the world's largest repository by 2021 by achieving conditional gene knockout of all 20,000 protein-coding genes in the mouse genome.
, the company launched the "aseptic rat program", access to the second domestic (the first in Jiangsu Province) aseptic animal production license, has begun to supply the market in bulk.
In addition, the company has been awarded by jiangsu province, Nanjing municipal government "new research and development institutions," "small and medium-sized enterprises in science and technology", "unicorn breeding enterprises" and many other honorary titles;
River (NYSE:CRL), the world's largest supplier of experimental animals, has Q1 revenue of $710 million in 2020, including $150 million in animal modeling and services.
envigo, the world's second-largest experimental animal company, is a merger of Huntinton and Harlan and employs more than 1,200 people in 20 international countries.
, the company needs to accelerate its global commercialization strategy, taking advantage of the quantitative advantages of animal resources and the ability to develop strong independent product line to rapidly expand into the international market.
, the world's largest provider of genetically modified animals, reported revenue of $317 million in 2018, up 11% year-on-year.
currently has about 11,000 mouse models and more than 2,200 employees.
, the world's second-largest provider of genetically modified animals, has annual revenues of about $150 million and more than 800 employees.
Compared with the two, if the market can accelerate the global commercial layout strategy, on the basis of the huge Chinese market, the use of new product line scale growth advantages and cost control capabilities, the future development of a huge space.
The national and global layout is beginning to take shape in the commercialization, the collection of pharmaceutical services is international (Europe and the United States, Southeast Asia, etc.), domestic (including Macau, Hong Kong, Taiwan, etc.) thousands of customers, including well-known domestic and foreign pharmaceutical companies, CRO companies and scientific research institutions.
, the company is also globally positioned as a world leader in the animal modeling industry.
established production and research and development bases in the western region and the Great Bay Area of Guangdong, Hong Kong and Macao.
In addition to Nanjing head office, there are currently a number of wholly-owned subsidiaries in the domestic layout of the collection of pharmaceutical kang, in Foshan, Guangdong and Changzhou, Jiangsu Province, the establishment of subsidiaries have been officially operated, in Chengdu, Sichuan, the construction of precision medicine specialty base is expected to be put into use in October.
by the end of 2020, the production capacity of mice raised in China will exceed 150,000 cages.
, the company is also actively promoting the development of bases in Europe and the United States, wholly-owned U.S. subsidiaries have completed registration and started operations.
drug collection kang plans to complete the construction of bases in Europe and the United States in 2021, the basic realization of the formation of a global layout.
In terms of domestic market development, up to now, it has covered nearly 400 research institutes such as The Chinese Academy of Sciences, Tsinghua University, Peking University, Shanghai Xuanda, Zhejiang University, Wuda University, Military Academy of Sciences, Zhongshan University, etc.; Hospital, nine hospitals, Renji Hospital, Qilu Hospital, Huaxi Hospital, Xiangya Hospital and other nearly 300 triple-A hospitals;
in the international network, the company and more than a dozen international resources to form exchanges and cooperation, has been with the United States, Canada, the United Kingdom, France, Japan, South Korea, Thailand and other forms of cooperation.
company's product line has become a very small number of domestic authorization to overseas, or directly overseas, or direct exports to the United States, Israel, Germany and other countries.
, through agent cooperation, and gradually expand the Korean and European markets.
in just two years, why has the company been able to gain the approval of head investment institutions such as Ding Yi Investment, China National Pharmaceutical Holdings, GaoSheng Ventures, Sequoia Capital, Morgan Stanley, and Yunfeng Fund? Behind years of experience in model animal construction is an experienced scientific and management team.
founder, Dr. Gao Xiang, since 2002, founded the Nanjing University Institute of Model Animals and the National Genetic Engineering Mouse Resource Bank, focusing on mouse model research, related research has won the second prize of national scientific and technological progress, the Ministry of Education science and technology progress award. Dr. Jing Zhao, CEO of
, has over 16 years of experience in model editing and analysis and major customer development, Dr. Yu Jianxiang, Director of Research and Development, has successfully developed hundreds of humanized animal models, and Dr. Wang Hongyu, Technical Director, graduated from Saar University in Germany and went on to oxford University in the United Kingdom for postdoctoral research, proficient in pattern building and drug screening.
as of May 2020, there are 268 research and development technical positions in the team of more than 500 people, accounting for 50% of the total number of teams, including 20 Doctorates.
doing academic research is Gao Xiang's strength, but they have never worked with capital markets before and know little about the financing process.
in round A financing, because of the company's rapid performance, even if only a small range of disclosure of financing intentions, there are more than 20 institutions have expressed investment intentions.
Gaoxiang selected five of them and found some good friends to help with staff.
after comparing the investment institutions and project management teams, in the end, the company chose Dingyu Investment and State Pharmaceutical Holdings, and even declined several institutions that offered higher valuations until a few days before signing the contract.
why did you choose Ding Ting Ting Capital? Gao Xiang's explanation is: "Ding Yi Investment is a trustworthy institution, Dingyu's investment team is also very real and sincere."
Many of the people Wang General (Ding Wei Wang) know are also my friends, whether before or after investment, in cross-border mergers and acquisitions, transaction structure design and other aspects, DingYi's rich experience will bring help to the company, Dingyi invested in a lot of industry head enterprises, know how to deal with head enterprises, and head enterprise founder's common quality, we also have the value of learning.
" and in ding-dong investment eyes, the collection of pharmaceutical health is also a suitable investment target.
Wang Wei, founding partner of Dingyi Investment, said:
In-depth accumulation and innovation in the field of gene-editing animals, the company has established a high level of technology and know-how barriers.
With Professor Gao Xiang as the core of the research and development management team is the 'national team', has the strength, passion, method, we believe they will be able to lead China to develop high-quality model animals to the world.
"We sincerely welcome new investors such as Gao Wei to join the board of directors and shareholders' meetings, and we will work with the company to help the company become the world's leading model animal leader," said Dr. Dan Liu, Executive Director of the Dingyu Investment Innovation and Growth Fund and Director of The Collection Of Pharmaceuticals.
" life sciences has been the active focus of ding-dong innovation and growth fund layout of the sector.
has now laid out a new drug discovery platform with DNA coding library as the core of Chengdu pilot, all-human antibody platform enterprises and platinum medicine, the domestic leading cancer immunopharmaceutical development enterprises Kowang Bio and the domestic leading stem cell treatment technology and dual-specific antibody development platform standards, and achieved excellent return on investment.
same time, the B-round financing lead investment agency Gao Wei Ventures in the pharmaceutical sector has also made a heavy bet, the field of health care is also the largest number of investments in recent years.
To the company's next development, Gao Xiang, founder of The Extractive Pharmaceuticals, said, "With this round of B financing, the company will continue to provide one-stop support services for life sciences research institutions around the world as well as clinical development of new pharmaceutical companies."
In the short term, we want mice to be a 'simulated stand-in' for clinical patients, to meet the research and development needs of academy institutions, pharmaceutical companies, etc., and in the long term, we hope to lead the trend of new drug research and development through the creation of new models."
"